Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=41665344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091695(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma AgfiledCriticalBayer Schering Pharma Ag
Publication of PE20091695A1publicationCriticalpatent/PE20091695A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
REFERIDA A UNA COMBINACION FARMACEUTICA QUE COMPRENDE DE 1,5 MG A 3,0 MG DE DROSPIRENONA (DRSP) Y DE 1 ,0 MG A 2,0 MG DE 17BETA-ESTRADIOL (E2). DICHA COMBINACION TAMBIEN CONTIENE DE 0,1 MG A 10 MG DE 5-METIL-(6S)-TETRAHIDROFOLATO Y ES UTIL PARA LA CONTRACEPCION Y TERAPIA HORMONAL EN MUJERES PERIMENOPAUSICASREFERRING TO A PHARMACEUTICAL COMBINATION INCLUDING FROM 1.5 MG TO 3.0 MG OF DROSPIRENONE (DRSP) AND FROM 1.0 MG TO 2.0 MG OF 17BETA-ESTRADIOL (E2). SUCH COMBINATION ALSO CONTAINS FROM 0.1 MG TO 10 MG OF 5-METHYL- (6S) -TETRAHYDROPHOLATE AND IS USEFUL FOR CONTRACEPTION AND HORMONE THERAPY IN PERIMENOPAUSAL WOMEN
PE2009000375A2008-03-132009-03-13
PHARMACEUTICAL COMBINATION OF DROSPIRENONE AND 17ß-ESTRADIOL
PE20091695A1
(en)
OPHTHALMIC COMPOSITION INCLUDING AN ANDROGEN AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF AN EYE DISEASE RESULTING FROM AN ANDROGENIC DEFICIENCY
USE OF ESTRADIOL VALERAT OR 17B-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL TREATMENT TO MAINTAIN AND / OR INCREASE SEXUAL TREATMENT IN THE SPECIAL WOMAN
PHARMACEUTICAL COMPOSITION INCLUDING DROSPIRENONE AND 17BETA ESTRADIOL; PHARMACEUTICAL KIT THAT INCLUDES SUCH COMPOSITION, USEFUL FOR HORMONAL THERAPY AND CONTRACEPTION IN WOMEN.
Pharmaceutical composition comprising 0.5-5 mg of (11?, 17?) - 17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one ; oral dosage form; use to treat and / or prevent a gynecological disease, such as fibroids in the uterus, endometriosis or excessive menstrual hemorrhages.
USE OF GESTAGANS IN COMBINATION WITH (6S) -5-METHYLTHETHRAHYDROPHOLATE FOR THERAPY ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPEUTIC COLLATERAL EFFECTS, AND REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS AT THE BEGINNING OF BEGINNING
PHARMACEUTICAL COMPOSITION UNDERSTANDING THE COMBINATION OF AN ANTIANDROGEN AGENT, A SYNTHETIC ESTEROID STROGEN AGENT AND VITAMIN AGENTS, USEFUL FOR THE CONTROL AND TREATMENT OF LATE ACNE IN WOMEN
USE OF A GESTAGEN IN COMBINATION WITH A STRATEGEN AND ONE OR VARIOUS EXCIPIENTS / PHARMACEUTICALLY ACCEPTABLE CARRIERS FOR ORACT-FREE ANTI-CONCEPTION WITHOUT LACTOSE